tiprankstipranks
Zelira Therapeutics Secures R&D Tax Incentive Boost
Company Announcements

Zelira Therapeutics Secures R&D Tax Incentive Boost

Zelira Therapeutics Ltd. (AU:ZLD) has released an update.

Don't Miss Our Christmas Offers:

Zelira Therapeutics Ltd., a leader in developing clinically validated cannabis medicines, has received a $919,000 cash refund from the Australian Federal Government’s R&D Tax Incentive Scheme. The funds will bolster working capital, aiding the progression of Zelira’s clinical development programs and business operations. The company is advancing its proprietary treatments, including a novel cannabinoid-based medicine, and is expanding its commercial presence internationally.

For further insights into AU:ZLD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Issues Convertible Notes
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Issues 3.5 Million Convertible Notes
TipRanks Australian Auto-Generated NewsdeskZelira Therapeutics Unveils Growth Plans at Investment Conference
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App